Castellano
Electoral Census
Electronic Office
Share
X
Facebook
Linkedin
WhatsApp
E-Mail
Copy to clipboard
INEbase
Research and development
Science and technology
Statistics on Biotechnology Use
Results year 2022
National Summary
National Summary
Business Sector
Biotechnology indicators by relevance of biotechnology in the company's activity.
Units:
Specified in each variable
Select values to consult
Indicator type
Values that contain
Companies carrying out R&D in Biotechnology
% Companies by type of biotechnology used: Genetic Code
% Companies by type of biotechnology used: Functional Units
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering
% Companies by type of biotechnology used: Bioprocesses
% Companies by type of biotechnology used: Subcellular Organisms
% Companies by type of biotechnology used: Bioinformatics
% Companies by type of biotechnology used: Nanobiotechnology
% Companies by type of biotechnology used: Other
% Companies by final application areas of biotechnology use: Human Health
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture
% Companies by final application areas of biotechnology use: Food Products
% Companies by final application areas of biotechnology use: Agriculture and Forestry
% Companies by final application areas of biotechnology use: Environment
% Companies by final application areas of biotechnology use: Industry
R&D personnel in Biotechnology (PP)
R&D personnel in Biotechnology (PP): Research personnel
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel
R&D personnel in Biotechnology (PP). Women
R&D personnel in Biotechnology (PP). Women: Research personnel
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel
R&D personnel in Biotechnology (FTE)
R&D personnel in Biotechnology (FTE): Research personnel
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel
R&D personnel in Biotechnology (FTE). Women
R&D personnel in Biotechnology (FTE). Women: Research personnel
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel
Expenditure on internal R&D in Biotechnology (thousands of euros)
1) By type of expenditure: Current expenditure
1.1) Labour expenditure of research personnel
1.2) Labour expenditure of technical and auxiliary personnel
1.3) Other current expenditure
2) By type of expenditure: Capital expenditure
2.1) Land and buildings
2.2) Equipment and tools
2.3) Acquisition of specific R&D software
2.4) Other R&D-specific IP products
1.1) By origin of funds: Own funds
1.2) By origin of funds: Funds from the Business sector
1.3) By origin of funds: Funds from the Public Administration sector
1.4) By origin of funds: Funds from the Higher Education sector
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector
1.6) By origin of funds: Funds from the rest of the world
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting
% Companies with international revenues related to biotechnology activities
% Companies representing international revenues related to biotechnology activities
% International revenues related to biotechnology activities distributed in: Revenues from the EU
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world
% International revenues related to biotechnology activities by classification: International trade in goods and services
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain
% International revenues related to biotechnology activities by classification: Subsidies from external sources
% International revenues related to biotechnology activities by classification: Other
Selected:
64
Total:
64
Main activity, secondary activity or tool required for...
Values that contain
Total
Main
Secondary
Tool required
Selected:
1
Total:
4
Choose format of the table
Main activity, secondary activity or tool required for...
Indicator type
.
.
.
.
.
.
.
.
.
Decimals to show:
By default
0
1
Notes
1) Data referring to all companies that carry out internal R&D in Biotechnology. 2) ' .'= numeric data equal to zero not resulting from rounding 3) FTE: Full-Time Equivalence
Total:
0
series
y
0
cells
Source:National Statistics Institute
